Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel (ciltacel) in lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy: CARTITUDE-2 Cohort A

被引：0

作者：

Cohen, Adam ^{[1
]}

Einsele, Hermann ^{[2
]}

Delforge, Michel ^{[3
]}

Hillengass, Jens ^{[4
]}

Goldschmidt, Hartmut ^{[5
,6
]}

Weisel, Katja ^{[7
]}

Raab, Marc-Steffen ^{[8
,9
]}

Scheid, Christof ^{[10
]}

Schecter, Jordan ^{[11
]}

De Braganca, Kevin ^{[11
]}

Varsos, Helen ^{[11
]}

Yeh, Tzu-min ^{[11
]}

Mistry, Pankaj ^{[12
]}

Roccia, Tito ^{[11
]}

Corsale, Christina ^{[13
]}

Akram, Muhammad ^{[14
]}

Pacaud, Lida ^{[14
]}

Nesheiwat, Tonia ^{[14
]}

Agha, Mounzer ^{[15
]}

Cohen, Yael ^{[16
,17
]}

机构：

[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[2] Univ Hosp Wurzburg, Dept Med 2, Wurzburg, Germany

[3] Univ Leuven, Leuven, Belgium

[4] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[5] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany

[6] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[7] Univ Med Ctr Hamburg Eppendorf, Sect Pneumol, Dept Oncol Hematol & Bone Marrow Transplan, Hamburg, Germany

[8] Univ Hosp Heidelberg, Heidelberg, Germany

[9] German Canc Res Ctr, Clin Cooperat Unit Mol Hematol Oncol, Heidelberg, Germany

[10] Univ Cologne, Cologne, Germany

[11] Janssen R&D, Raritan, NJ USA

[12] Janssen R&D, High Wycombe, Bucks, England

[13] Janssen Global Serv LLC, Raritan, NJ USA

[14] Legend Biotech USA, Piscataway, NJ USA

[15] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[16] Tel Aviv Univ, Ichilov Med Ctr, Tel Aviv, Israel

[17] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OAB-045

引用

页码：S27 / S28

页数：2

共 32 条

[1] Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup
Cohen, Adam D.
Voorhees, Peter M.
Martin, Thomas G.
Lesokhin, Alexander M.
Hillengass, Jens
Kaufman, Jonathan L.
Schecter, Jordan Mark
De Braganca, Kevin C.
Varsos, Helen
Corsale, Christina
Mistry, Pankaj
Song, Qingxuan
Koneru, Mythili
Akram, Muhammad
Costa Filho, Octavio
Einsele, Hermann
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in LenalidomideRefractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)
Hillengass, Jens
Cohen, Adam D.
Delforge, Michel
Einsele, Hermann
Goldschmidt, Hartmut
Weisel, Katja
Raab, Marc-Steffen
Scheid, Christof
Schecter, Jordan M.
De Braganca, Kevin C.
Varsos, Helen
Yeh, Tzu-min
Mistry, Pankaj
Roccia, Tito
Corsale, Christina
Akram, Muhammad
Pacaud, Lida
Nesheiwat, Tonia
Agha, Mounzer
Cohen, Yael C.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S411 - S411
[3] Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1-3 prior lines of therapy (LOT): CARTITUDE-2, cohort A.
Einsele, Hermann
Cohen, Adam D.
Delforge, Michel
Hillengass, Jens
Goldschmidt, Hartmut
Weisel, Katja
Raab, Marc-Steffen
Scheid, Christof
Schecter, Jordan Mark
De Braganca, Kevin C.
Varsos, Helen
Yeh, Tzu-Min
Mistry, Pankaj
Roccia, Tito
Corsale, Christina
Akram, Muhammad
Bubuteishvili-Pacaud, Lida
Nesheiwat, Tonia
Agha, Mounzer E.
Cohen, Yael C.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma After 1-3 Prior Lines of Therapy: Updated Results From CARTITUDE-2 Cohort A
Cohen, Yael C.
Cohen, Adam D.
Delforge, Michel
Hillengass, Jens
Goldschmidt, Hartmut
Weisel, Katja
Raab, Marc-Steffen
Scheid, Christoph
Schecter, Jordan M.
De Braganca, Kevin C.
Varsos, Helen
Yeh, Tzu-Min
Wang, Liwei
Vogel, Martin
Corsale, Christina
Akram, Muhammad
Pacaud, Lida
Nesheiwat, Tonia
Agha, Mounzer
Einsele, Hermann
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 34 - 35
[5] Ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma and early relapse after initial therapy: biological correlative analyses and updated clinical results from CARTITUDE-2 Cohort B
Agha, Mounzer
van de Donk, Niels W. C. J.
Cohen, Adam
Cohen, Yael
Anguille, Sebastien
Kerre, Tessa
Roeloffzen, Wilfried
Schecter, Jordan
De Braganca, Kevin
Varsos, Helen
Mistry, Pankaj
Roccia, Tito
Zudaire, Enrique
Corsale, Christina
Akram, Muhammad
Geng, Dong
Nesheiwat, Tonia
Pacaud, Lida
Sonneveld, Pieter
Zweegman, Sonja
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S26 - S26
[6] CARTITUDE-2 LONG-TERM EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL FOR PATIENTS WITH MULTIPLE MYELOMA AND 1-3 PRIOR LINES OF THERAPY (COHORT A) AND WITH EARLY RELAPSE ( COHORT B)
Glow, Tina
Whittington, Sara
Cohen, Adam
Varsos, Helen
Akram, Muhammad
Hillengass, Jens
ONCOLOGY NURSING FORUM, 2024, 51 (02)
[7] The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)
Hillengass, Jens
Cohen, Adam D.
Agha, Mounzer E.
Delforge, Michel
Kerre, Tessa
Roeloffzen, Wilfried
Einsele, Hermann
Goldschmidt, Hartmut
Weisel, Katja
Raab, Marc S.
Scheid, Christof
Anguille, Sebastien
Sonneveld, Pieter
Zweegman, Sonja
Schecter, Jordan M.
de Braganca, Kevin C.
Jackson, Carolyn Chang
Vlummens, Philip
Varsos, Helen
Corsale, Christina
Madduri, Deepu
Yeh, Tzu-Min
Mistry, Pankaj
Roccia, Tito
Song, Qingxuan
Akram, Muhammad
Costa Filho, Octavio
Geng, Dong
Cohen, Yael C.
van de Donk, Niels W. C. J.
BLOOD, 2023, 142
[8] EFFICACY AND ADVERSE EVENTS AFTER CILTACABTAGENE AUTOLEUCEL TREATMENT IN THE CARTITUDE-4 AS-TREATED POPULATION CONSISTING OF PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA WHO RECEIVED 1-3 PRIOR LINES OF THERAPY
Applewhite, Ishmael
Elfrink, Gwen
Esselmann, Jean
Lonardi, Carolina
Florendo, Erika
Sidiqi, M. Hasib
ONCOLOGY NURSING FORUM, 2024, 51 (02)
[9] EFFECT OF CILTACABTAGENE AUTOLEUCEL VERSUS STANDARD-OF-CARE ON PATIENT-REPORTED OUTCOMES IN THE CARTITUDE-4 TRIAL OF PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY
Gries, Katharine
Tran, Linh
Appenfeller, Allison
Folkers, Anna
Florendo, Erika
Mina, Roberto
ONCOLOGY NURSING FORUM, 2024, 51 (02)
[10] Infections and Immune Reconstitution in the Phase 3 CARTITUDE-4 Trial of Ciltacabtagene Autoleucel vs Standard Care in Patients with Lenalidomide-Refractory Multiple Myeloma (MM) and 1-3 Prior Lines
van de Donk, Niels
Martinez-Lopez, Joaquin
Dhakal, Binod
Dutka, Magdalena
Shune, Leyla
Touzeau, Cyrille
Leleu, Xavier
Cohen, Yael
Alsdorf, Winfried
Mina, Roberto
Li, Katherine
Zhao, Man
Li, Quanlin
Ghosh, Arnab
Ghosh, Arnab
Vogel, Martin
Lendvai, Nikoletta
Slaughter, Ana
Lonardi, Carolina
Plaks, Vicki
Koneru, Mythili
Patel, Nitin
Florendo, Erika
Oriol, Albert
Popat, Rakesh
Ho, P. Joy
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S94 - S94

← 1 2 3 4 →